Thursday 16 October, 2025
The pharmacokinetics of ciprofloxacin in plasma and lung tissue was studied in 36 patients undergoing surgery. A compartment model was…
Read moreposter
Experiences With CYP-2D6 Polymorphism In Clinical Drug Development
Thursday 16 October, 2025
During the drug development process compounds that exhibit large (unexplained) interindividual variability in plasma concentrations may fail to be advanced…
Read moreProspective Evaluation Of A Formula To Predict Carboplatin Clearance In Children
Thursday 16 October, 2025
In paediatric patients, relationships between carboplatin haematological toxicity and plasma ultrafilterable carboplatin AUC have been observed. They were more significant…
Read moreIncorporation Of Population Pharmacokinetic Principles Into Drug Development
Thursday 16 October, 2025
A retrospective pharmacokinetic (PK) analysis of data from a number of Phase I studies has been performed implementing the population…
Read moreThe Population Pharmacokinetics Of Ondansetron: A Covariate Analysis
Thursday 16 October, 2025
Ondansetron is a potent and selective 5-HT3 antagonist that is used to prevent and treat chemotherapy and radiotherapy induced nausea…
Read morePopulation Pharmacokinetics/ Pharmacodynamics Of Fluindione In Patients.
Thursday 16 October, 2025
Fluindione is an oral anticoagulant with a long half-life that inhibits the synthesis of vitamin K-dependent clotting factors. It is…
Read moreAssessment Of Liver Blood Flow Using A Continuous Infusion Of A Drug With High Hepatic Clearance
Thursday 16 October, 2025
Hepatic blood flow is a major determinant in the rate of elimination of so-called high clearance drugs. Knowledge about this…
Read moreAssessment Of Covariate Relationships In The Analysis Of The Population Pharmacokinetics Of Tacrolimus.
Thursday 16 October, 2025
The population pharmacokinetics of the immunosuppressant drug tacrolimus were investigated in 172 patients, aged 18-66 years, following liver transplantation. Tacrolimus…
Read morePopulation Pharmacokinetics Of A New Bradycardic Agent In Healthy Male Volunteers: Influence Of Food And Time Of Administration
Thursday 16 October, 2025
S-16257 is a bradycardic agent potentially developed for the treatment of myocardial ischaemia. It belongs to the class of specific…
Read morePopulation Pharmacokinetics Of Tobramycin In Neonates
Thursday 16 October, 2025
Tobramycin is commomly used in newborn infants with suspected or proved bacterial infection. The serum concentrations of tobramycin are routinely…
Read more